A Randomized Trial in Healthy Subjects to Assess the Bioequivalence of an Atazanavir/Cobicistat Fixed-Dose Combination Tablet versus Administration as Separate Agents
Antiviral Therapy2014Vol. 20(5), pp. 493–500
Citations Over TimeTop 21% of 2014 papers
Heather Sevinsky, Xiaolu Tao, Reena Wang, Palanikumar Ravindran, Karen Sims, Xiaohui Xu, Navin Jariwala, Richard Bertz
Abstract
ATV/COBI (300/150 mg) FDC tablet was bioequivalent to coadministration as separate agents with a light meal in healthy subjects. Clinicaltrials.gov identifier NCT01837719.
Related Papers
- → Cobicistat: A Review of Its Use as a Pharmacokinetic Enhancer of Atazanavir and Darunavir in Patients with HIV-1 Infection(2013)99 cited
- Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat.(2015)
- → Atazanavir sulfate + cobicistat for the treatment of HIV infection(2017)9 cited
- → Cobicistat: a guide to its use as a pharmacokinetic enhancer of atazanavir and darunavir in HIV-1 infection(2014)2 cited
- → Cobicistat vs. Ritonavir as a Booster for Atazanavir(2011)